Faculty Bibliography
Searched for:
in-biosketch:true
person:kruppl01
Total Results:
616
The Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) patient cohort [Meeting Abstract]
ISI:000453090803247
ISSN: 0028-3878
CID: 3561842
A Case of Cognitive and Behavioral Decline leading to Onset of Pediatric Onset Multiple Sclerosis [Meeting Abstract]
ISI:000453090801288
ISSN: 0028-3878
CID: 3561992
Expanding the phenotype of ATP1A3 mutations with newly described abnormalities on brain MRI [Meeting Abstract]
ISI:000453090800307
ISSN: 0028-3878
CID: 3561492
Patterns of Use and Safety of Newer Disease-modifying therapies in Pediatric Multiple Sclerosis in the US [Meeting Abstract]
ISI:000453090806044
ISSN: 0028-3878
CID: 3561382
Computerized Measurement of Processing Speed Predicts Cognitive Decline in Pediatric Onset Multiple Sclerosis [Meeting Abstract]
ISI:000453090803224
ISSN: 0028-3878
CID: 3561852
Long term outcome from a randomized double-blind remotely supervised tDCS trial for symptomatic management in multiple sclerosis [Meeting Abstract]
ISI:000453090803332
ISSN: 0028-3878
CID: 3561812
Effects of Fingolimod on MRI Outcomes in Patients with Pediatric Onset Multiple Sclerosis: Results from Phase 3 PARADIGMS Study [Meeting Abstract]
ISI:000453090806045
ISSN: 0028-3878
CID: 3561642
Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing
BACKGROUND: Cognitive impairment is a common and troubling feature of pediatric-onset multiple sclerosis (POMS). Brief cognitive assessment in the outpatient setting can identify and longitudinally monitor cognitive involvement so that early intervention is possible. OBJECTIVES: The goal of this study was to measure the sensitivity of two cognitive assessment approaches that are brief, repeatable, and suitable for clinical practice and for multicenter investigation. METHODS: Participants with POMS ( n = 69) were consecutively evaluated as part of outpatient neurologic visits and compared to healthy control participants (HC, n = 66) using the Brief International Cognitive Assessment for MS (BICAMS) approach and timed information processing measures from Cogstate, a computer-based assessment. RESULTS: There was strong agreement in the detection rate of impairment between both assessments, with 26% for the BICAMS and 27% for Cogstate. Two of the Cogstate tasks were the most sensitive individual measures. CONCLUSION: Both the BICAMS and Cogstate timed processing measures offer practical, sensitive, and standardized approaches for cognitive screening assessment in POMS.
PMID: 28322606
ISSN: 1477-0970
CID: 2499402
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
BACKGROUND:modulator, on disability progression in patients with SPMS. METHODS:This event-driven and exposure-driven, double-blind, phase 3 trial was done at 292 hospital clinics and specialised multiple sclerosis centres in 31 countries. Using interactive response technology to assign numbers linked to treatment arms, patients (age 18-60 years) with SPMS and an Expanded Disability Status Scale score of 3·0-6·5 were randomly assigned (2:1) to once daily oral siponimod 2 mg or placebo for up to 3 years or until the occurrence of a prespecified number of confirmed disability progression (CDP) events. The primary endpoint was time to 3-month CDP. Efficacy was assessed for the full analysis set (ie, all randomly assigned and treated patients); safety was assessed for the safety set. This trial is registered with ClinicalTrials.gov, number NCT01665144. FINDINGS:1651 patients were randomly assigned between Feb 5, 2013, and June 2, 2015 (1105 to the siponimod group, and 546 to the placebo group). One patient did not sign the consent form, and five patients did not receive study drug, all of whom were in the siponimod group. 1645 patients were included in the analyses (1099 in the siponimod group and 546 in the placebo). At baseline, the mean time since first multiple sclerosis symptoms was 16·8 years (SD 8·3), and the mean time since conversion to SPMS was 3·8 years (SD 3·5); 1055 (64%) patients had not relapsed in the previous 2 years, and 918 (56%) of 1651 needed walking assistance. 903 (82%) patients receiving siponimod and 424 (78%) patients receiving placebo completed the study. 288 (26%) of 1096 patients receiving siponimod and 173 (32%) of 545 patients receiving placebo had 3-month CDP (hazard ratio 0·79, 95% CI 0·65-0·95; relative risk reduction 21%; p=0·013). Adverse events occurred in 975 (89%) of 1099 patients receiving siponimod versus 445 (82%) of 546 patients receiving placebo; serious adverse events were reported for 197 (18%) patients in the siponimod group versus 83 (15%) patients in the placebo group. Lymphopenia, increased liver transaminase concentration, bradycardia and bradyarrhythmia at treatment initiation, macular oedema, hypertension, varicella zoster reactivation, and convulsions occurred more frequently with siponimod than with placebo. Initial dose titration mitigated cardiac first-dose effects. Frequencies of infections, malignancies, and fatalities did not differ between groups. INTERPRETATION:Siponimod reduced the risk of disability progression with a safety profile similar to that of other S1P modulators and is likely to be a useful treatment for SPMS. FUNDING:Novartis Pharma AG.
PMID: 29576505
ISSN: 1474-547x
CID: 5348122
The Paradigms Study: A Randomized Double-Blind Trial of Fingolimod Versus Interferon beta-1a in Patients with Multiple Sclerosis Aged 10 to < 18 Years [Meeting Abstract]
ISI:000429034600048
ISSN: 1352-4585
CID: 3039262
